Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Q3 2024 Earnings Call Transcript November 18, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the NRx ...

In the Guidance, the FDA posits that poor pharmaceutical label design can contribute to medication errors. To reduce such errors, the FDA seemingly takes a "pro-trade dress" stance by warning ...

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

With the rise in global counterfeiting operations, stakeholders need to be aware of their responsibility when it comes to pharmaceutical goods and their legitimacy. Companies can make this task easier ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

Additionally, the broad US label for Yorvipath allows treatment of ... These developments underscore significant upside potential for Ascendis Pharma’s late-stage programs, leading to the ...

Elite's product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under ...

Navi Mumbai-based Intergraphic Sales and Services sold two Pulisi kits, the DSmart 330 F digital press and the PAIM370S ...

Shares of Elite Pharmaceuticals, Inc. ELTP have gained 12.2% since the company released its earnings for the quarter ended ...

Adial Pharmaceuticals completes PK study for AD04 in AUD, meeting FDA requirements and preparing for Phase 3 trial. Data supports 505(b)(2) application.